The positive Phase 1 data significantly de-risks the subcutaneous BRIUMVI program, which could nearly double the addressable market if approved. Traders should watch for Phase 3 top-line data (late 2026/early 2027) and the device bridging study later this year. The stock has strong historical momentum on positive pipeline catalysts.
Price Chart
Executive Summary
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing favorable pharmacokinetics, safety, and tolerability. The data support the ongoing Phase 3 trial evaluating quarterly subcutaneous dosing, with top-line Phase 3 results expected year-end 2026 or early 2027. If approved, subcutaneous BRIUMVI could be the first self-administered, at-home, quarterly anti-CD20 therapy for multiple sclerosis, potentially doubling the addressable market for the BRIUMVI franchise.
Key Facts
- Phase 1 data showed mean bioavailability >60% vs IV, with lower bound of 95% CI exceeding 55%.
- PK modeling supports non-inferior total drug exposure for quarterly SC dosing (GMR 1.21, lower bound 90% CI 1.15) vs IV.
- No new safety signals; local injection-site reactions in <5% of patients; systemic injection reactions in ~21%, all resolved.
- Phase 3 trial fully enrolled; top-line results expected late 2026 or early 2027; potential approval in 2028.
- SC BRIUMVI could be first self-administered, at-home, quarterly anti-CD20 therapy for MS, potentially doubling addressable market.
- Over 100 patients treated in Phase 1; more than 225 SC injections administered, >75% at 400 mg dose.
Financial Impact
No financial figures provided in filing. Market cap is $5.6B. Positive Phase 1 data de-risks Phase 3 and supports potential market expansion for BRIUMVI franchise.
Risk Factors
- Phase 3 trial may fail to meet primary endpoint despite positive Phase 1 data.
- Regulatory approval not guaranteed; FDA may require additional studies.
- Commercial adoption of SC formulation may be slower than anticipated.
- Competition from other anti-CD20 therapies and MS treatments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-019262 |
| Document: tgtx20260602_8k.htm | 0001437749-26-019262 |
| Document: 0001437749-26-019262-index-headers.html | 0001437749-26-019262 |
| Document: 0001437749-26-019262-index.html | 0001437749-26-019262 |
| Document: 0001437749-26-019262.txt | 0001437749-26-019262 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | — | awaiting T+60 | — | — |
Aug 3, 2026 12w ago | 8-K | $46.17 $55.99 | ▲ +21.27% | ▲ +19.49% | $56.44 (+22.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $49.52 $55.74 | ▲ +12.56% | ▲ +9.30% | $56.44 (+13.97%) |
Jun 3, 2026 20w ago | 8-K | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.44 (+40.71%) |
Jun 3, 2026 20w ago | Press Release | $40.11 $55.72 | ▲ +38.92% | ▲ +36.42% | $56.44 (+40.71%) |
Jun 1, 2026 21w ago | Press Release | $37.41 $55.42 | ▲ +48.14% | ▲ +46.91% | $56.44 (+50.87%) |
May 27, 2026 21w ago | 8-K | $38.82 $54.27 | ▲ +39.80% | ▲ +38.06% | $56.44 (+45.39%) |
May 6, 2026 24w ago | 8-K | $41.97 $52.03 | ▲ +23.97% | ▲ +21.91% | $56.44 (+34.48%) |
Apr 30, 2026 25w ago | Press Release | $33.78 $55.75 | ▲ +65.04% | ▲ +61.93% | $56.44 (+67.08%) |
Apr 22, 2026 26w ago | Press Release | $38.31 $54.87 | ▲ +43.23% | ▲ +38.45% | $56.44 (+47.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers